3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
17
Lymphoma, Non-Hodgkin
4
Lymphoma, B-Cell
4
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hodgkin Disease
2
Recurrence
1
Neoplasms
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
22
fludarabine
20
venetoclax
8
Whole-Body Irradiation
8
Mycophenolic Acid
8
Standard of Care
6
Mesna
6
Melphalan
6
Azacitidine
6
fludarabine phosphate
5
Sirolimus
5
thymoglobulin
4
Thiotepa
4
Tacrolimus
4
Specimen Handling
4
Filgrastim
4
Cytarabine
4
entrectinib
3
daratumumab
3
cobimetinib
3
alectinib
3
Vemurafenib
3
Surveys and Questionnaires
3
Rituximab
3
Practice Guidelines as Topic
3
Palliative Care
3
Granulocyte Colony-Stimulating Factor
3
Busulfan
3
Bortezomib
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hematologic Neoplasms
×
polatuzumab vedotin
×
Clear all
NCT04844866
2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2
Recruiting
213 enrolled